دورية أكاديمية
أعرض في EDS

RNA Vaccines against Infectious Diseases: Vital Progress with Room for Improvement.

التفاصيل البيبلوغرافية
العنوان: RNA Vaccines against Infectious Diseases: Vital Progress with Room for Improvement.
المؤلفون: Abdelzaher HM; Institute of Global Public Health, School of Sciences and Engineering, The American University in Cairo, Cairo 11835, Egypt., Gabr AS; Institute of Global Public Health, School of Sciences and Engineering, The American University in Cairo, Cairo 11835, Egypt., Saleh BM; Institute of Global Public Health, School of Sciences and Engineering, The American University in Cairo, Cairo 11835, Egypt., Abdel Gawad RM; Institute of Global Public Health, School of Sciences and Engineering, The American University in Cairo, Cairo 11835, Egypt., Nour AA; Institute of Global Public Health, School of Sciences and Engineering, The American University in Cairo, Cairo 11835, Egypt., Abdelanser A; Institute of Global Public Health, School of Sciences and Engineering, The American University in Cairo, Cairo 11835, Egypt.
المصدر: Vaccines [Vaccines (Basel)] 2021 Oct 20; Vol. 9 (11). Date of Electronic Publication: 2021 Oct 20.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101629355 Publication Model: Electronic Cited Medium: Print ISSN: 2076-393X (Print) Linking ISSN: 2076393X NLM ISO Abbreviation: Vaccines (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI AG
مستخلص: mRNA vaccines have amassed a strong interest from scientists and nonscientists alike for their potential in treating cancer and curbing the spread of infectious diseases. Their success has been bolstered by the COVID-19 pandemic as mRNA vaccines for the SARS-CoV-2 virus showed unrivaled efficiency and success. The strategy relies on the delivery of an RNA transcript that carries the sequence of an antigenic molecule into the body's cells where the antigen is manufactured. The lack of use of infectious pathogens and the fact that they are made of nucleic acids render these vaccines a favorable alternative to other vaccination modalities. However, mRNA vaccination still suffers from a great deal of hurdles starting from their safety, cellular delivery, uptake and response to their manufacturing, logistics and storage. In this review, we examine the premise of RNA vaccination starting from their conceptualization to their clinical applications. We also thoroughly discuss the advances in the field of RNA vaccination for infectious diseases. Finally, we discuss the challenges impeding their progress and shed light on potential areas of research in the field.
References: Mol Ther. 2021 Jun 2;29(6):1970-1983. (PMID: 33823303)
N Engl J Med. 2020 Dec 31;383(27):2603-2615. (PMID: 33301246)
Lancet. 2021 Jun 26;397(10293):2461-2462. (PMID: 34139198)
MMWR Morb Mortal Wkly Rep. 2021 May 07;70(18):674-679. (PMID: 33956782)
Vaccine. 2018 Mar 14;36(12):1689-1699. (PMID: 29456015)
Science. 2018 Mar 23;359(6382):1355-1360. (PMID: 29567706)
Mol Ther. 2019 Apr 10;27(4):757-772. (PMID: 30803823)
Adv Drug Deliv Rev. 2021 Mar;170:1-25. (PMID: 33359141)
Cell Death Differ. 2021 Feb;28(2):626-639. (PMID: 33479399)
Mol Ther. 2008 Nov;16(11):1833-40. (PMID: 18797453)
Pharmaceutics. 2021 Feb 02;13(2):. (PMID: 33540942)
Vaccine. 2016 Jul 19;34(33):3882-93. (PMID: 27269061)
Biotechnol J. 2015 Sep;10(9):1329-44. (PMID: 26212697)
Gene Ther. 2021 Apr;28(3-4):117-129. (PMID: 33093657)
N Engl J Med. 2020 Nov 12;383(20):1920-1931. (PMID: 32663912)
Rheumatol Int. 2021 Mar;41(3):509-518. (PMID: 33515320)
Cancer Res. 2010 Nov 15;70(22):9031-40. (PMID: 21045153)
Cell. 2017 Mar 9;168(6):1114-1125.e10. (PMID: 28222903)
Nucleic Acids Res. 1995 May 11;23(9):1495-501. (PMID: 7784202)
N Engl J Med. 2021 Apr 15;384(15):1412-1423. (PMID: 33626250)
Proc Natl Acad Sci U S A. 2016 Jul 19;113(29):E4133-42. (PMID: 27382155)
N Engl J Med. 2021 Aug 12;385(7):661-662. (PMID: 34161700)
Nature. 2016 Jun 01;534(7607):396-401. (PMID: 27281205)
Int J Mol Sci. 2020 Sep 09;21(18):. (PMID: 32916818)
Cancer Res. 1995 Apr 1;55(7):1397-400. (PMID: 7882341)
N Engl J Med. 2020 Jun 18;382(25):2469-2471. (PMID: 32558474)
Vaccine. 2019 May 31;37(25):3326-3334. (PMID: 31079849)
Science. 2021 Mar 12;371(6534):1152-1153. (PMID: 33514629)
AIDS Res Hum Retroviruses. 2018 Jan;34(1):111-122. (PMID: 28636433)
RNA Biol. 2012 Nov;9(11):1319-30. (PMID: 23064118)
NPJ Vaccines. 2021 Feb 22;6(1):28. (PMID: 33619260)
Genome Med. 2017 Jun 27;9(1):60. (PMID: 28655327)
J Acquir Immune Defic Syndr. 2016 Mar 1;71(3):246-53. (PMID: 26379068)
Vaccine. 1994 Dec;12(16):1510-4. (PMID: 7879415)
BMC Med. 2018 Jun 6;16(1):84. (PMID: 29871628)
Drug Des Devel Ther. 2018 Dec 10;12:4195-4206. (PMID: 30573950)
Science. 1990 Mar 23;247(4949 Pt 1):1465-8. (PMID: 1690918)
Nature. 2020 Oct;586(7830):589-593. (PMID: 32785213)
Gene Ther. 2007 Aug;14(15):1175-80. (PMID: 17476302)
Curr Biol. 2015 Jun 29;25(13):R526-32. (PMID: 26126273)
N Engl J Med. 2021 Jun 17;384(24):2273-2282. (PMID: 33882218)
EMBO Mol Med. 2017 Oct;9(10):1434-1447. (PMID: 28794134)
Vaccine. 2021 Apr 15;39(16):2190-2200. (PMID: 33771389)
J Pharm Sci. 2021 Mar;110(3):997-1001. (PMID: 33321139)
Nature. 2021 Jan;589(7841):189-191. (PMID: 33437061)
NPJ Vaccines. 2021 Apr 16;6(1):57. (PMID: 33863911)
N Engl J Med. 2021 Feb 4;384(5):403-416. (PMID: 33378609)
Lancet Microbe. 2021 Mar;2(3):e89-e90. (PMID: 33659918)
J Immunother Cancer. 2015 Jun 16;3:26. (PMID: 26082837)
Nat Rev Drug Discov. 2018 Apr;17(4):261-279. (PMID: 29326426)
Immunol Rev. 2004 Jun;199:251-63. (PMID: 15233739)
Vaccines (Basel). 2019 Sep 27;7(4):. (PMID: 31569785)
Sci Immunol. 2019 May 17;4(35):. (PMID: 31101672)
Expert Rev Vaccines. 2015 Feb;14(2):221-34. (PMID: 25540984)
Nat Rev Immunol. 2021 Apr;21(4):195-197. (PMID: 33674759)
Mol Cancer. 2021 Feb 16;20(1):33. (PMID: 33593376)
Nature. 2017 Mar 9;543(7644):248-251. (PMID: 28151488)
Vaccines (Basel). 2019 Dec 06;7(4):. (PMID: 31817794)
Mol Ther. 2017 Jun 7;25(6):1316-1327. (PMID: 28457665)
J Infect Dis. 2018 Jan 17;217(3):451-455. (PMID: 29281112)
Nat Commun. 2020 Jul 9;11(1):3523. (PMID: 32647131)
J Clin Invest. 2020 Nov 2;130(11):5976-5988. (PMID: 33016924)
N Engl J Med. 2021 Aug 12;385(7):585-594. (PMID: 34289274)
Cell Rep. 2018 Jul 10;24(2):406-418. (PMID: 29996101)
Eur J Immunol. 1993 Jul;23(7):1719-22. (PMID: 8325342)
Front Immunol. 2018 Sep 19;9:1963. (PMID: 30283434)
Mol Ther. 2019 Apr 10;27(4):710-728. (PMID: 30846391)
Transplantation. 2021 Oct 1;105(10):2170-2174. (PMID: 33859151)
Vaccine. 2021 Feb 22;39(8):1310-1318. (PMID: 33487468)
Curr Top Microbiol Immunol. 2022;440:111-145. (PMID: 32300916)
Biochem Pharmacol. 2016 Nov 15;120:1-14. (PMID: 27157411)
J Immunother. 2009 Jun;32(5):498-507. (PMID: 19609242)
Wien Klin Wochenschr. 2021 Sep;133(17-18):931-941. (PMID: 34378087)
Pharmaceutics. 2020 Jan 28;12(2):. (PMID: 32013049)
Front Immunol. 2019 Mar 27;10:594. (PMID: 30972078)
Am J Transplant. 2021 Aug;21(8):2916-2918. (PMID: 34101990)
Proc Natl Acad Sci U S A. 1989 Aug;86(16):6077-81. (PMID: 2762315)
Sci Immunol. 2021 Apr 15;6(58):. (PMID: 33858945)
Clin Exp Vaccine Res. 2012 Jul;1(1):18-34. (PMID: 23596575)
N Engl J Med. 2021 Jan 7;384(1):80-82. (PMID: 33270381)
Expert Rev Vaccines. 2018 Dec;17(12):1105-1110. (PMID: 30422031)
Vaccine. 2021 Jan 15;39(3):457-459. (PMID: 33339671)
JAMA. 2021 Jun 1;325(21):2204-2206. (PMID: 33950155)
Drug Discov Today. 2020 Sep;25(9):1556-1558. (PMID: 32592866)
Front Microbiol. 2020 Feb 28;11:298. (PMID: 32265848)
Cell. 2020 Sep 3;182(5):1271-1283.e16. (PMID: 32795413)
فهرسة مساهمة: Keywords: SARS-CoV-2; challenges; clinical trials; infectious diseases; mRNA vaccines
تواريخ الأحداث: Date Created: 20211127 Latest Revision: 20231108
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC8622374
DOI: 10.3390/vaccines9111211
PMID: 34835142
قاعدة البيانات: MEDLINE
الوصف
تدمد:2076-393X
DOI:10.3390/vaccines9111211